An overview of how different payers prioritize safety and tolerability profiles when assessing new therapies. MARA Rating Insight Since 2020, assets averaging a 3.3 Safety score cleared HTA hurdles more often than those
A concise overview of the essential Health Technology Assessment domains every drug developer must address. Use this checklist to design and execute development programs that directly address payer needs across
Market Access Risk Assessment MARA Rating Company Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy
Use this checklist to rapid-fire your due diligence – ensure each asset in your portfolio meets critical payer evidence expectations across all ten domains. The 10 Critical P&R Due Diligence
Breaking the Bias: Why Market-Access Teams Must Avoid Common Thinking Traps in Pharma Acquisitions Many M&A teams do not pay enough attention to market-access risks. Yet simple thinking errors on
MARA Rating Insight Since 2020, assets averaging a 3.1 Cost-Effectiveness score sailed through HTA evaluations, while those at just 1.96 were far more likely rejected. That 1.14-point gap often determines whether payers call your
Market Access Professionals: Your Definitive HTA Checklist for a Smooth P&R Journey Use this checklist as a self-assessment tool to ensure your dossier covers all critical evidence domains. Simply run
Every payer’s checklist is different. MARA Rating Insight Since 2020, assets with an average Clinical Effectiveness score of 3.1 sailed through HTA evaluations, while those averaging just 2.7 were more often rejected. That 0.4-point
Over the past five years, almost half of drug launches have fallen short of their sales forecasts due to misjudged pricing and reimbursement (P & R) risks, resulting in significant